AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

Core Viewpoint - The agreement to acquire rights outside of China for a portfolio of experimental obesity and diabetes drugs has a potential valuation in the billions of dollars [1] Group 1 - The deal involves rights to a portfolio of drugs targeting obesity and diabetes [1] - The valuation of the agreement could reach billions, indicating significant market potential [1]